The development of ensifentrine, the first PDE inhibitor that can be administered by nebulization, is an important advance in the therapy of COPD, especially for patients presenting with COPD exacerbations [17,33,34,35,36,37]. Here, ALDH7A1 is linked to chronic obstructive pulmonary disease.